Genetic Variation in KCNH2 Associated With Expression in the Brain of a Unique hERG Isoform Modulates Treatment Response in Patients With Schizophrenia

Clinical Brain Disorders Branch, Genes, Cognition, and Psychosis Program, Intramural Research Program, NIMH, Bethesda, MD 20877, USA.
American Journal of Psychiatry (Impact Factor: 12.3). 06/2012; 169(7):725-34. DOI: 10.1176/appi.ajp.2012.11081214
Source: PubMed


Antidopaminergic drugs bind to hERG1 potassium channels encoded by the gene KCNH2, which accounts for the side effect of QT interval prolongation. KCNH2 has also been associated with schizophrenia risk, and risk alleles predict increased expression of a brain-selective isoform, KCNH2 3.1, that has unique physiological properties. The authors assessed whether genetic variation associated with KCNH2 3.1 expression influences the therapeutic effects of antipsychotic drugs.
The authors performed a pharmacogenetic analysis of antipsychotic treatment response in patients with schizophrenia using data from two independent studies: a National Institute of Mental Health (NIMH) double-blind, placebo-controlled inpatient crossover trial (N=54) and the multicenter outpatient Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) study (N=364). The KCNH2 genotype that was previously associated with increased expression of KCNH2 3.1 in the brain was treated as a predictor variable. Treatment-associated changes in symptoms were evaluated in both groups with the Positive and Negative Syndrome Scale. The authors also analyzed time to discontinuation in the olanzapine arm of the CATIE study.
In the NIMH study, individuals who were homozygous for the KCNH2 3.1 increased expression-associated T allele of rs1036145 showed significant improvement in positive symptoms, general psychopathology, and thought disturbance, while patients with other genotypes showed little change. In the CATIE study, analogous significant genotypic effects were observed. Moreover, individuals who were homozygous for the T allele at rs1036145 were one-fifth as likely to discontinue olanzapine.
These consistent findings in two markedly different treatment studies support the hypothesis that hERG1-mediated effects of antipsychotics may not be limited to their potential cardiovascular side effects but may also involve therapeutic actions related to the brainspecific 3.1 isoform of KCNH2.

Download full-text


Available from: Kristin L Bigos, Oct 27, 2015
  • Source
    • "Antipsychotic Treatment Response in the CBDB/NIMH Cohort Treatment effects were observed on several neuropsychiatric symptoms and syndromal clusters ascertained from the PANSS ratings (Supplementary Table S1 and Apud et al, 2012). Overall, medications significantly improved symptoms, including those comprising the positive syndrome (Estimate ¼ À 1.3565, p ¼ 0.0007), general psychopathology (Estimate ¼ À 2.2851, p ¼ 0.0093), thought disturbance (Estimate ¼ À 0.8928, p ¼ 0.0004), and activation (Estimate ¼ À 0.6841, p ¼ 0.0018). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neurexins are presynaptic neuronal adhesion molecules that interact with postsynaptic neuroligins to form an inter-synaptic complex required for synaptic specification and efficient neurotransmission. Deletions and point mutations in the neurexin 1 (NRXN1) gene are associated with a broad spectrum of neuropsychiatric and neurodevelopmental disorders including, autism, intellectual disability, epilepsy, developmental delay and schizophrenia. Recently, small nucleotide polymorphisms in NRXN1 have been associated with antipsychotic drug response in patients with schizophrenia. Based on prior suggestive evidence of an impact on clozapine response in patients with schizophrenia, we conducted an association study of NRXN1 polymorphisms (rs12467557 and rs10490162) with antipsychotic treatment response in fifty-four patients with schizophrenia in a double blind, placebo-controlled NIMH inpatient crossover trial and examined for association with risk for schizophrenia in independent case-control and family-based clinical cohorts. Pharmacogenetic analysis in the placebo controlled trial revealed significant association of rs12467557and rs10490162 with drug response, whereby individuals homozygous for the A allele, at either SNP, showed significant improvement in positive symptoms, general psychopathology, thought disturbance and negative symptoms, while patients carrying the G allele showed no overall response. While we did not find evidence of the same NRXN1 SNPs being associated with results of the NIMH sponsored CATIE trial, other SNPs showed weakly positive signals. The family and case controls analyses for schizophrenia risk were negative. Our results provide confirmatory evidence of genetically determined differences in drug response in patients with schizophrenia related to NRXN1 variation. Furthermore, these findings potentially implicate NRXN1 in the therapeutic actions of antipsychotic drugs.
    Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 03/2014; 39(9). DOI:10.1038/npp.2014.65 · 7.05 Impact Factor
  • Source

    American Journal of Psychiatry 07/2012; 169(7):681-3. DOI:10.1176/appi.ajp.2012.12040457 · 12.30 Impact Factor
  • Source

    American Journal of Psychiatry 07/2012; 169(7):678-80. DOI:10.1176/appi.ajp.2012.12040538 · 12.30 Impact Factor
Show more